drugset / Trial / NCT02629224

ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis

NCT02629224

Phase 1 Completed 18 enrolled Astellas Pharma Inc
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the pharmacokinetics and safety of ASP8825 in patients with impaired renal function and haemodialysis.

Timeline

Start
2008-02
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject gabapentin enacarbil Small molecule Oral

Indications

No indication recorded.